Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades

Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades

Protein kinase inhibitors (PKIs) are important therapeutic agents. As of 31 May 2021, the United States Food and Drug Administration (USFDA) has approved 70 PKIs. Most of the PKIs are employed to treat cancer and inflammatory diseases. Imatinib was the first PKI approved by USFDA in 2001. This revie...

Full description

Bibliographic Details
Main Authors: Mohd. Imran, Syed Mohammed Basheeruddin Asdaq, Shah Alam Khan, Dhanalekshmi Unnikrishnan Meenakshi, Abdulhakeem S. Alamri, Walaa F. Alsanie, Majid Alhomrani, Yahya Mohzari, Ahmed Alrashed, Mohammed AlMotairi, Eman H. Alkhaldi, Abeer K. Alorabi, Ahmed Subeh Alshrari, Mohammad Tauseef, Abida, Saleh I. Alaqel, Ozair Alam, Md. Afroz Bakht
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Pharmaceuticals
Subjects:
protein kinase inhibitors
USFDA
cancer
inflammation
patent review
generic product
Online Access:https://www.mdpi.com/1424-8247/14/8/710

Internet

https://www.mdpi.com/1424-8247/14/8/710

Similar Items